Innovative Medicines Initiative Launches ‘ADAPT SMART’, an Adaptive Pathways Project with 32 International Participants
The project will establish a platform that enables the coordination of Medicines Adaptive Pathways to Patients (MAPPs) related activities within the Innovative Medicines Initiative (IMI) and engages in dialogue with all relevant stakeholders. MAPPs seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion. The outcomes of the ADAPT SMART consortium will help inform future research agendas and discuss approaches for the implementation of MAPPs.
(4 September 2015 – London, United Kingdom): ADAPT SMART, a European public-private collaboration bringing together 32 international participants, is launched today at a meeting hosted by the European Medicines Agency (EMA) in London.
ADAPT SMART (Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes) is a multi-stakeholder project focused on laying the foundations for “Medicines Adaptive Pathways to Patients” (MAPPs) to be put into practice in Europe. MAPPs has the potential to bring new medicines to patients faster. ADAPT SMART will investigate MAPPs tools and methodologies, and engage all relevant stakeholders to develop workable MAPPs concepts. The project is led by the EMA and coordinated by TI Pharma via its regulatory innovation platform ‘Escher’, and is supported by a number of public and industry partners.